Literature DB >> 22346378

A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens.

R J Davidson1, D E Low.   

Abstract

OBJECTIVE: To determine the prevalence of antimicrobial resistance in clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis from medical centres across Canada.
METHODS: Fifty laboratories from across Canada were asked to collect up to 25 consecutive clinical isolates of S pneumoniae, H influenzae and M catarrhalis at some time between September 1994 and May 1995, and then again between September and December of 1996. A total of 2364 S pneumoniae, 575 H influenzae and 200 M catarrhalis samples were collected. H influenzae and M catarrhalis isolates were tested for the production of beta-lactamase. S pneumoniae isolates were characterized as penicillin susceptible, intermediately resistant or high level penicillin-resistant. Minimal inhibitory concentrations (MICs) were determined using a microbroth dilution technique described by the National Committee of Clinical Laboratory Standards.
RESULTS: Between the two collection periods, there was a significant increase in highly penicillin-resistant S pneumoniae from 2.1% to 4.4% (P<0.05) and an increase in intermediately penicillin-resistant strains from 6.4% to 8.9% (P<0.05). A significant increase in high level penicillin-resistant S pneumoniae was noted among paediatric isolates. No significant difference in the susceptibilities of comparator agents was detected. A significant increase in the number of beta-lactamase producing H influenzae, 34% to 43% (P<0.05) was observed. Ninety-five per cent of M catarrhalis isolates were beta-lactamase producers in both time periods.
CONCLUSIONS: During the course of this study, the incidence of penicillin resistance in S pneumoniae doubled. As a result of this increase, infections due to this organism in sites where poor penetration of beta-lactam antibiotics occur may become increasingly difficult to manage.

Entities:  

Keywords:  Antimicrobial resistance; Respiratory tract pathogens

Year:  1999        PMID: 22346378      PMCID: PMC3250720          DOI: 10.1155/1999/278586

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  32 in total

1.  Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.

Authors:  P P Gleason; W N Kapoor; R A Stone; J R Lave; D S Obrosky; R Schulz; D E Singer; C M Coley; T J Marrie; M J Fine
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

2.  Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993.

Authors:  K Muhlemann; M Balz; S Aebi; K Schopfer
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians.

Authors:  R Gonzales; J F Steiner; M A Sande
Journal:  JAMA       Date:  1997-09-17       Impact factor: 56.272

4.  Recent trends in pediatric Haemophilus influenzae type B infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control.

Authors:  D W Scheifele
Journal:  CMAJ       Date:  1996-04-01       Impact factor: 8.262

5.  Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae.

Authors:  P V Adrian; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics.

Authors:  C G Dowson; T J Coffey; B G Spratt
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

7.  Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae Study Group.

Authors:  G Urwin; J A Krohn; K Deaver-Robinson; J D Wenger; M M Farley
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

Review 8.  Genetics and molecular biology of beta-lactam-resistant pneumococci.

Authors:  T J Coffey; C G Dowson; M Daniels; B G Spratt
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

9.  Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin.

Authors:  R Dagan; O Abramson; E Leibovitz; R Lang; S Goshen; D Greenberg; P Yagupsky; A Leiberman; D M Fliss
Journal:  Pediatr Infect Dis J       Date:  1996-11       Impact factor: 2.129

Review 10.  Comparison of macrolide antibiotics.

Authors:  J D Williams; A M Sefton
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

View more
  6 in total

1.  Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.

Authors:  D Hardy; D Amsterdam; L A Mandell; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  How Nova Scotia general practitioners choose antibiotics for the empirical treatment of community-acquired pneumonia.

Authors:  J Pendergrast; T J Marrie
Journal:  Can J Infect Dis       Date:  2000-11

4.  Reduced susceptibility to penicillin among pneumococci causing invasive infection in children - Canada, 1991 to 1998.

Authors:  D Scheifele; S Halperin; L Pelletier; J Talbot; M Lovgren; W Vaudry; T Jadavji; B Law; N Macdonald; R Gold; E Wang; E Mills; M Lebel; P Déry; R Morris
Journal:  Can J Infect Dis       Date:  2001-07

5.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

6.  Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group.

Authors:  G G Zhanel; J A Karlowsky; L Palatnick; L Vercaigne; D E Low; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.